Triumph Capital Management
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1730765
DENVER, CO
Position in REGN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$292,830
+$14,185 QoQ
Shares Held
379
+5.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Triumph Capital Management holds $2,157,226 across 19 Biotechnology names. REGN ranks #4 (13.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
9,894 | $931,223 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
2,545 | $481,132 | |
| 3 | ARQT |
Arcutis Biotherapeutics, Inc.
|
15,135 | $356,580 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
This page
|
379 | $292,830 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
131 | $58,496 | |
| 6 | MRNA |
Moderna, Inc.
|
300 | $15,240 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
100 | $4,757 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
50 | $3,754 |
All Filings in REGN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $292,830 | 379 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $278,645 | 361 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $261,455 | 465 | Shares | Sole | 2025-12-23 | |
| 2025-06-30 | $442,575 | 843 | Shares | Sole | 2025-12-29 | |
| 2025-03-31 | $375,464 | 592 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $398,904 | 560 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $444,674 | 423 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||